Selection between sunitinib and ripretinib using mutation analysis for gastrointestinal stromal tumor patients progressing on imatinib

被引：0
|
作者：
Joensuu, Heikki [1 ,2 ]
机构：
[1] Helsinki Univ Hosp, Dept Oncol, POB 180,Haartmaninkatu 4, Helsinki 00029, Finland
[2] Univ Helsinki, POB 180,Haartmaninkatu 4, Helsinki 00029, Finland
来源：
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 9卷
关键词：
Gastrointestinal stromal tumor (GIST); imatinib; sunitinib; ripretinib; PHASE-II TRIAL; KINASE INHIBITOR; EFFICACY; KIT; RESISTANCE; SCHEDULE; MESYLATE; SAFETY;
D O I：
10.21037/tgh-24-32
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    Shirao, Kuniaki
    Nishida, Toshirou
    Doi, Toshihiko
    Komatsu, Yoshito
    Muro, Kei
    Li, Yinhua
    Ueda, Eiji
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) : 866 - 875
  • [32] Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
    Brohl, Andrew S.
    Demicco, Elizabeth G.
    Mourtzikos, Karen
    Maki, Robert G.
    CLINICAL SARCOMA RESEARCH, 2015, 5
  • [33] Surgical. resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal. tumor treated with sunitinib
    Ruka, W.
    Rutkowski, P.
    Szawlowski, A.
    Nowecki, Z.
    Debiec-Rychter, M.
    Grzesiakowska, U.
    Dziewirski, W.
    Siedlecki, J. A.
    Michej, W.
    EJSO, 2009, 35 (01): : 87 - 91
  • [34] Hepatic Artery Embolization for Liver Metastasis of Gastrointestinal Stromal Tumor Following Imatinib and Sunitinib Therapy
    Takaki H.
    Litchman T.
    Covey A.
    Cornelis F.
    Maybody M.
    Getrajdman G.I.
    Sofocleous C.T.
    Brown K.T.
    Solomon S.B.
    Alago W.
    Erinjeri J.P.
    Journal of Gastrointestinal Cancer, 2014, 45 (4) : 494 - 499
  • [35] Efficacy of Sunitinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
    Cubukcu, Sinem
    Kanat, Ozkan
    Cubukcu, Erdem
    Olmez, Omer Fatih
    Canhoroz, Mustafa
    Avci, Nilufer
    Hartavi, Mustafa
    Deligonul, Adem
    Seyhan, Serdar
    Ayyildiz, Aylin
    Tasdemir, Unal
    Manavoglu, Osman
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2014, 5 (04)
  • [36] Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Tielen, Ronald
    Verhoef, Cornelis
    van Coevorden, Frits
    Gelderblom, Hans
    Sleijfer, Stefan
    Hartgrink, Henk H.
    Bonenkamp, Johannes J.
    van der Graaf, Winette T.
    de Wilt, Johannes H. W.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [37] Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor
    Zheng, Song
    Pan, Yue-Long
    Tao, De-You
    Wang, Jiao-Li
    Huang, Ke-Er
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (06) : 760 - 763
  • [38] Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Ronald Tielen
    Cornelis Verhoef
    Frits van Coevorden
    Hans Gelderblom
    Stefan Sleijfer
    Henk H Hartgrink
    Johannes J Bonenkamp
    Winette T van der Graaf
    Johannes H W de Wilt
    World Journal of Surgical Oncology, 10
  • [39] Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor
    Wu, Xin
    Li, Jian
    Xu, Wentong
    Gao, Jing
    Li, Yanyan
    Shen, Lin
    FUTURE ONCOLOGY, 2018, 14 (17) : 1721 - 1729
  • [40] Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
    Yoon, Shinkyo
    Ryu, Min-Hee
    Yoo, Changhoon
    Beck, Mo Youl
    Ryoo, Baek-Yeol
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (08) : 1248 - 1252
12345